[ Price : $8.95]
Centessa Pharmaceuticals reports encouraging clinical data for its oral OX2R agonist ORX750 in patients with narcolepsy Types 1 an...[ Price : $8.95]
FDA warns Liebel-Flarsheim in Raleigh, NC, about CGMP violations in its production of finished drugs.[ Price : $8.95]
FDA releases the form FDA-483 with four observations from an inspection at the Alembic Pharmaceuticals active pharmaceutical ingre...[ Price : $8.95]
A STAT report highlighted in Medpage says CBER employees are concerned about the environment established by their new director, Vi...[ Price : $8.95]
FDA issues Biohaven a complete response letter, rejecting the companys NDA for Vyglxia (troriluzole) as a treatment for spinocereb...[ Price : $8.95]
FDA issues a Warning Letter to Apotex, citing significant GMP violations at the companys Richmond Hill, Ontario, facility, includi...[ Price : $8.95]
Politico reports that President Trump and HHS are standing by FDA commissioner Marty Makary as the agency weathers the sudden depa...[ Price : $8.95]
Sydnexis says its SYD-101 drug to treat pediatric progressive myopia met both the primary and key secondary endpoints in the Phase...